• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Why Jazz Pharmaceuticals (JAZZ) Is Down 6.3% After Ziihera’s First-Line HER2-Positive GEA Survival Data And What's Next

    Simply Wall St·09/02/2026 03:24:26
    Listen to the news
    • In late August 2026, Jazz Pharmaceuticals reported second interim Phase 3 HERIZON-GEA-01 data and confirmed prior US FDA approvals showing that Ziihera (zanidatamab-hrii), in combinations with chemotherapy with or without Tevimbra (tislelizumab), delivered statistically significant overall survival gains over trastuzumab-based regimens in first-line HER2-positive advanced gastroesophageal adenocarcinoma.
    • By securing US approval for the first bispecific HER2-targeted antibody plus PD-1 inhibitor and chemotherapy regimen in this setting, Jazz has positioned Ziihera as a potential new standard of care while also advancing a broad HER2-positive solid tumor program under multiple Breakthrough Therapy and Orphan Drug designations.
    • We’ll now examine how Ziihera’s new first-line HER2-positive GEA approval and survival benefit could influence Jazz Pharmaceuticals’ broader investment narrative.

    We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

    Jazz Pharmaceuticals Investment Narrative Recap

    To own Jazz Pharmaceuticals today, you need to believe the company can offset looming oxybate patent expirations and pricing pressure by scaling newer oncology and neuroscience assets. The Ziihera survival benefit and first line HER2 positive GEA approval sharpen that near term oncology catalyst, but they do not remove the key risk that a concentrated pipeline and high debt could weigh on earnings if newer launches underperform.

    The most relevant recent announcement here is the US FDA approval of two Ziihera containing first line GEA regimens on August 25, 2026. This approval validates the HERIZON GEA 01 data, gives Jazz a differentiated entrant in HER2 positive GEA and ties directly into the broader HER2 solid tumor program that analysts already viewed as central to offsetting erosion in the legacy sleep franchise.

    Yet against that progress, investors should still be aware of how heavy reliance on a few late stage assets could...

    Read the full narrative on Jazz Pharmaceuticals (it's free!)

    Jazz Pharmaceuticals' narrative projects $5.7 billion revenue and $1.6 billion earnings by 2029. This requires 7.2% yearly revenue growth and about a $659 million earnings increase from $940.8 million today.

    Uncover how Jazz Pharmaceuticals' forecasts yield a $281.35 fair value, a 15% upside to its current price.

    Exploring Other Perspectives

    JAZZ 1-Year Stock Price Chart
    JAZZ 1-Year Stock Price Chart

    Some of the lowest ranked analysts were far more cautious, assuming only about US$4.8 billion of revenue and roughly US$1.1 billion of earnings by 2029, so if you worry that Ziihera launch risks or pricing pressure might hold Jazz back, it is worth comparing that pessimistic view against more optimistic takes that this latest approval could shift expectations.

    Explore 4 other fair value estimates on Jazz Pharmaceuticals - why the stock might be worth 13% less than the current price!

    Reach Your Own Conclusion

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Ready For A Different Approach?

    These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.